Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2016

View Archived Issues

Homology Medicines gains rights to AAV technology from Caltech

First patient dosed in phase Ib study of Xencor's XmAB-7195

Eisai launches AiM Institute

Promising immunotherapy for type 1 diabetes tested in phase I study

AcelRx Pharmaceuticals's ARX-04 well tolerated in phase III trial

DSMB recommends continuation of Celsion's phase Ib OVATION study

Long QT syndrome patients with triple gene mutations have more severe symptoms

FDA approves Aralez Pharmaceuticals' Yosprala

Phase III results reported for ertugliflozin in addition to metformin and sitagliptin for diabetes

Pfizer initiates phase IIa trial of PF-06480605 in moderate to severe ulcerative colitis

Nitto Denko patents carboxylesterase inhibitors

Inotrem completes phase I study of Motrem

Dosing begins in phase I study of Calithera Biosciences' CB-1158

GSK begins dosing patients in phase I study of PRMT5 inhibitor

Liraglutide may exert epigenetic effect in T2DM patients

National Cancer Center of Japan and Ono sign comprehensive research collaboration agreement

Novartis explores anticancer effects of inhibiting the COP9 signalosome

Astellas Pharma forms partnership with Courtagen Life Sciences

FDA grants QIDP status to Viamet Pharmaceuticals' VT-1598

Trek Therapeutics reports results from phase IIa study of triple-drug combo for HCV

Gene Techno Science initiates phase III trial of darbepoetin alfa biosimilar in Japan

New biomarker signature predicts microvascular outcomes in dysglycemia

EMA's CHMP recommends conditional approval of Lilly's olaratumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...